A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)

Byeong Bae Park,Won-Seog Kim,Cheolwon Suh,Jung Yong Hong,Deok-Hwan Yang,Won Sik Lee,Young Rok Do,Young Il Koh,Jong-Ho Won,Min Kyoung Kim,Jae-Cheol Jo,Shin Young Hyun,Jeong-A Kim,Young-Ha Oh,Seung-Sook Lee

A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)

2019

Byeong Bae Park
Won-Seog Kim
Cheolwon Suh
Jung Yong Hong
Deok-Hwan Yang
Won Sik Lee
Young Rok Do
Young Il Koh
Jong-Ho Won
Min Kyoung Kim
Jae-Cheol Jo
Shin Young Hyun
Jeong-A Kim
Young-Ha Oh
Seung-Sook Lee

AbstractThis trial was designed to investigate the efficacy and toxicity of bendamustine, carboplatin, and dexamethasone (BCD) for relapsed or refractory peripheral T-cell lymphomas (PTCLs), which ...

Keywords:

Toxicity
Dexamethasone
Oncology
Peripheral
Immunology
Diabetes mellitus
Medicine
Bendamustine
Refractory
Internal medicine
Salvage therapy
Carboplatin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations